MUC13 promotes lung cancer development and progression by activating ERK signaling

Pang,Yao; Zhang,Yu; Zhang,Hong-Yi; Wang,Wen-Hao; Jin,Gang; Liu,Jia-Wei; Zhu,Zi-Jiang

doi:10.3892/ol.2021.13155

MUC13 promotes lung cancer development and progression by activating ERK signaling

Authors:
- Yao Pang
- Yu Zhang
- Hong-Yi Zhang
- Wen-Hao Wang
- Gang Jin
- Jia-Wei Liu
- Zi-Jiang Zhu
View Affiliations

Affiliations: Department of Thoracic Surgery No. 2, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China, Department of Clinical Medicine, Gansu Health Vocational College, Lanzhou, Gansu 730000, P.R. China
Published online on: December 1, 2021 https://doi.org/10.3892/ol.2021.13155
Article Number: 37
Copyright: © Pang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mucin 13 (MUC13) is a glycoprotein that is expressed on the cell surface and participates in the tumorigenesis of multiple malignancies, including pancreatic cancer, colorectal cancer and renal cancer. However, to the best of our knowledge, the expression levels and function of MUC13 in lung cancer progression have not yet been demonstrated. Therefore, the present study examined the expression pattern and regulatory role of MUC13 in lung cancer tumorigenesis. The results demonstrated that MUC13 was highly expressed in lung cancer tissues and cell lines compared with that in normal tissues and cell lines. Functionally, knockdown of MUC13 inhibited cell proliferation and enhanced the apoptosis of A549 and NCI‑H1650 lung cancer cells. Furthermore, silencing of MUC13 suppressed the migration and invasion of lung cancer cells. Additionally, a xenograft tumor model demonstrated that knockdown of MUC13 delayed the development of the lung cancer xenograft and suppressed the expression of proliferation marker Ki‑67 in tumor tissues. Mechanistically, MUC13 activated the ERK signaling pathway by enhancing the phosphorylation of ERK, JNK and p38 in lung cancer tissues compared with that in normal tissues. Knockdown of MUC13 inhibited the phosphorylation of ERK/JNK/p38 in A549 and NCI‑H1650 cells. Overall, these findings suggested that MUC13 could act as an oncogenic glycoprotein to accelerate the progression of lung cancer via abnormal activation of the ERK/JNK/p38 signaling pathway and might serve as a therapeutic target for lung cancer treatment.

View Figures

View References

1	Bade BC and Dela Cruz CS: Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med. 41:1–24. 2020. View Article : Google Scholar : PubMed/NCBI
2	Yang D, Liu Y, Bai C, Wang X and Powell CA: Epidemiology of lung cancer and lung cancer screening programs in China and the United States. Cancer Lett. 468:82–87. 2020. View Article : Google Scholar : PubMed/NCBI
3	Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current therapies and new targeted treatments. Lancet. 389:299–311. 2017. View Article : Google Scholar : PubMed/NCBI
4	Liu WJ, Du Y, Wen R, Yang M and Xu J: Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. Pharmacol Ther. 206:1074382020. View Article : Google Scholar : PubMed/NCBI
5	Yan X, Jiao SC, Zhang GQ, Guan Y and Wang JL: Tumor-associated immune factors are associated with recurrence and metastasis in non-small cell lung cancer. Cancer Gene Ther. 24:57–63. 2017. View Article : Google Scholar : PubMed/NCBI
6	Hung JJ, Jeng WJ, Hsu WH, Chou TY, Huang BS and Wu YC: Predictors of death, local recurrence, and distant metastasis in completely resected pathological stage-I non-small-cell lung cancer. J Thorac Oncol. 7:1115–1123. 2012. View Article : Google Scholar : PubMed/NCBI
7	Williams SJ, Wreschner DH, Tran M, Eyre HJ, Sutherland GR and McGuckin MA: Muc13, a novel human cell surface mucin expressed by epithelial and hemopoietic cells. J Biol Chem. 276:18327–18336. 2001. View Article : Google Scholar : PubMed/NCBI
8	Sheng YH, Lourie R, Lindén SK, Jeffery PL, Roche D, Tran TV, Png CW, Waterhouse N, Sutton P, Florin TH, et al: The MUC13 cell-surface mucin protects against intestinal inflammation by inhibiting epithelial cell apoptosis. Gut. 60:1661–1670. 2011. View Article : Google Scholar : PubMed/NCBI
9	Shimamura T, Ito H, Shibahara J, Watanabe A, Hippo Y, Taniguchi H, Chen Y, Kashima T, Ohtomo T, Tanioka F, et al: Overexpression of MUC13 is associated with intestinal-type gastric cancer. Cancer Sci. 96:265–273. 2005. View Article : Google Scholar : PubMed/NCBI
10	Chauhan SC, Vannatta K, Ebeling MC, Vinayek N, Watanabe A, Pandey KK, Bell MC, Koch MD, Aburatani H, Lio Y, et al: Expression and functions of transmembrane mucin MUC13 in ovarian cancer. Cancer Res. 69:765–774. 2009. View Article : Google Scholar : PubMed/NCBI
11	Chauhan SC, Ebeling MC, Maher DM, Koch MD, Watanabe A, Aburatani H, Lio Y and Jaggi M: MUC13 mucin augments pancreatic tumorigenesis. Mol Cancer Ther. 11:24–33. 2012. View Article : Google Scholar : PubMed/NCBI
12	Gupta BK, Maher DM, Ebeling MC, Stephenson PD, Puumala SE, Koch MR, Aburatani H, Jaggi M and Chauhan SC: Functions and regulation of MUC13 mucin in colon cancer cells. J Gastroenterol. 49:1378–1391. 2014. View Article : Google Scholar : PubMed/NCBI
13	Sheng YH, He Y, Hasnain SZ, Wang R, Tong H, Clarke DT, Lourie R, Oancea I, Wong KY, Lumley JW, et al: MUC13 protects colorectal cancer cells from death by activating the NF-κB pathway and is a potential therapeutic target. Oncogene. 36:700–713. 2017. View Article : Google Scholar : PubMed/NCBI
14	Tiemin P, Fanzheng M, Peng X, Jihua H, Ruipeng S, Yaliang L, Yan W, Junlin X, Qingfu L, Zhefeng H, et al: MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways. J Hepatol. 72:761–773. 2020. View Article : Google Scholar : PubMed/NCBI
15	Khan S, Ebeling MC, Zaman MS, Sikander M, Yallapu MM, Chauhan N, Yacoubian AM, Behrman SW, Zafar N, Kumar D, et al: MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget. 5:7599–7609. 2014. View Article : Google Scholar : PubMed/NCBI
16	He L, Qu L, Wei L, Chen Y and Suo J: Reduction of miR 132 3p contributes to gastric cancer proliferation by targeting MUC13. Mol Med Rep. 15:3055–3061. 2017. View Article : Google Scholar : PubMed/NCBI
17	Moniaux N, Escande F, Porchet N, Aubert JP and Batra SK: Structural organization and classification of the human mucin genes. Front Biosci. 6:D1192–D1206. 2001. View Article : Google Scholar : PubMed/NCBI
18	Filippou PS, Ren AH, Korbakis D, Dimitrakopoulos L, Soosaipillai A, Barak V, Frenkel S, Pe'er J, Lotem M, Merims S, et al: Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases. Clin Chem Lab Med. 56:1945–1953. 2018. View Article : Google Scholar : PubMed/NCBI
19	Lim W, Ridge CA, Nicholson AG and Mirsadraee S: The 8th lung cancer TNM classification and clinical stageing system: Review of the changes and clinical implications. Quant Imaging Med Surg. 8:709–718. 2018. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Δ Δ C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Kumari S, Khan S, Gupta SC, Kashyap VK, Yallapu MM, Chauhan SC and Jaggi M: MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer. Oncogenesis. 7:192018. View Article : Google Scholar : PubMed/NCBI
22	Stiles ZE, Khan S, Patton KT, Jaggi M, Behrman SW and Chauhan SC: Transmembrane mucin MUC13 distinguishes intraductal papillary mucinous neoplasms from non-mucinous cysts and is associated with high-risk lesions. HPB (Oxford). 21:87–95. 2019. View Article : Google Scholar : PubMed/NCBI
23	Sheng Y, Ng CP, Lourie R, Shah ET, He Y, Wong KY, Seim I, Oancea I, Morais C, Jeffery PL, et al: MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance. Int J Cancer. 140:2351–2363. 2017. View Article : Google Scholar : PubMed/NCBI
24	Dai Y, Liu L, Zeng T, Liang JZ, Song Y, Chen K, Li Y, Chen L, Zhu YH, Li J, et al: Overexpression of MUC13, a poor prognostic predictor, promotes cell growth by activating Wnt signaling in hepatocellular carcinoma. Am J Pathol. 188:378–391. 2018. View Article : Google Scholar : PubMed/NCBI
25	Doxtater K, Sekhri R, Mishra U, Jaggi M, Tripathi M and Chauhan S: MUC13 enhances anchorage independent survival and cooperates with YAP1 and β-catenin towards colorectal cancer metastasis. Cancer Res. 80 (Suppl):49162020.
26	Wang H, Shen L, Lin Y, Shi Q, Yang Y and Chen K: The expression and prognostic significance of Mucin 13 and Mucin 20 in esophageal squamous cell carcinoma. J Cancer Res Ther. 11 (Suppl 1):C74–C79. 2015. View Article : Google Scholar : PubMed/NCBI
27	Li P, Wang H, Hou M, Li D and Bai H: Upstream stimulating factor1 (USF1) enhances the proliferation of glioblastoma stem cells mainly by activating the transcription of mucin13 (MUC13). Pharmazie. 72:98–102. 2017.PubMed/NCBI
28	Gupta BK, Maher DM, Ebeling MC, Sundram V, Koch MD, Lynch DW, Bohlmeyer T, Watanabe A, Aburatani H, Puumala SE, et al: Increased expression and aberrant localization of mucin 13 in metastatic colon cancer. J Histochem Cytochem. 60:822–831. 2012. View Article : Google Scholar : PubMed/NCBI
29	LaMonte GM, Orjuela-Sanchez P, Calla J, Wang LT, Li S, Swann J, Cowell AN, Zou BY, Abdel-Haleem Mohamed AM, Villa Galarce ZH, et al: Dual RNA-seq identifies human mucosal immunity protein Mucin-13 as a hallmark of Plasmodium exoerythrocytic infection. Nat Commun. 10:4882019. View Article : Google Scholar : PubMed/NCBI